Premaitha Health plc announced the appointment of Mr. Lyn Rees as Chief Executive Officer and Mr. Keng Hsu as Chief Operating Officer (Asia). Dr. Stephen Little, currently Chief Executive Officer, will move to the role of Executive Vice Chairman of the group. Alan Chang, Non-executive Director, will step down from the board with immediate effect to focus on his other business interests.

Lyn has significant healthcare sector leadership experience, having spent 18 years at the BBI Group, most recently as Group Chief Executive Officer, a position he held for nine years. During his tenure as Chief Executive Officer, Lyn oversaw the substantial growth of BBI through the execution and integration of a number of acquisitions and by driving an organic growth plan based around product diversification and commercial globalization. Lyn's appointment will enable Dr. Stephen Little to focus on the Group's continued technological development in his new role, leveraging the Company's existing scientific capabilities and expanding customer base to broaden the Group's product and service portfolio.

Mr. Keng Hsu was formerly Chief Financial Officer of Yourgene Bioscience prior to its acquisition by Premaitha in March 2017 and, since then, he has played a key role in Premaitha's senior management team and the Group's Asian.